Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ocean Biomedical Inc. (OCEAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OCEAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -28.57% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 37800 | Beta - | 52 Weeks Range 0.02 - 0.24 | Updated Date 02/26/2025 |
52 Weeks Range 0.02 - 0.24 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ocean Biomedical Inc.
Company Overview
History and Background
Ocean Biomedical Inc. was founded in 2019. It focuses on developing innovative therapeutics in oncology, fibrosis, and infectious diseases.
Core Business Areas
- Oncology: Developing therapies targeting cancer. This includes compounds focused on immune modulation and tumor microenvironment modification.
- Fibrosis: Researching and developing treatments for fibrotic diseases, addressing unmet medical needs in this area.
- Infectious Diseases: Developing therapeutics to combat infectious diseases. Focused on developing broad spectrum anti-malarial compounds.
Leadership and Structure
Dr. Chirinjeev Kathuria is the Co-Founder and Executive Chairman. The company has a scientific advisory board consisting of experts in its target therapeutic areas.
Top Products and Market Share
Key Offerings
- Anti-Malarial Compounds: Developing broad-spectrum anti-malarial compounds. Currently in preclinical development. Market share data is not yet available. Competitors include GlaxoSmithKline (GSK) and Novartis, which have existing malaria treatments.
- OXPT-007: OXPT-007 is a novel anti-cancer therapeutic targeting multiple cancer types. It is currently in preclinical development. Market share data is not yet available as it's not commercialized. Competitors include large pharmaceutical companies like Roche, Novartis, and Pfizer focusing on oncology.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and innovative. There is significant investment in oncology, fibrosis, and infectious diseases due to high unmet medical needs.
Positioning
Ocean Biomedical is positioned as an early-stage biotechnology company focusing on novel therapeutic approaches. Its competitive advantage lies in its innovative technology and partnerships with leading research institutions.
Total Addressable Market (TAM)
The TAM for oncology, fibrosis, and infectious disease therapeutics is estimated to be in the hundreds of billions of dollars. Ocean Biomedical is positioned to capture a portion of this TAM through successful development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced leadership team
- Partnerships with leading research institutions
- Focus on high unmet medical needs
Weaknesses
- Early stage of development
- Limited financial resources
- High regulatory risk
- Lack of commercialized products
Opportunities
- Potential for breakthrough therapies
- Partnerships with larger pharmaceutical companies
- Government funding and grants
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Failure to obtain regulatory approval
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- GSK
Competitive Landscape
Ocean Biomedical faces strong competition from established pharmaceutical companies with greater financial resources and established market presence. Its advantages lie in its innovative technology and focus on high unmet medical needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the company's progress in developing its therapeutic pipeline and securing funding.
Future Projections: Future growth is projected to be driven by the successful completion of clinical trials, regulatory approvals, and commercialization of its therapies. Analyst estimates vary.
Recent Initiatives: Recent strategic initiatives include partnerships with research institutions, expansion of the therapeutic pipeline, and pursuit of government funding.
Summary
Ocean Biomedical is an early-stage biotech company with a focus on oncology, fibrosis, and infectious diseases. Its strength lies in its innovative technology and partnerships. However, it faces challenges related to its early stage of development, limited financial resources, and regulatory risks. It needs to look out for competition from larger pharmaceutical companies and potential clinical trial failures.
Similar Companies
- MRNA
- VIR
- BNTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocean Biomedical Inc.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website |
Full time employees 9 | Website | ||
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.